ArticleJournal of pain research2026
Clinical Validation of Quality Indicators for the Pharmacological Management of Chronic Non-Cancer Pain in Older Adult Inpatients.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Chronic non-cancer pain (CNCP) affects up to 88% of older adults. Pharmacological therapies are frequently prescribed long-term despite being considered second-line treatments and carrying significant risks, particularly for older adults. The present study aimed to clinically validate a set of quality indicators (QIs) that are used to improve the detection of medication-related problems during medication reviews performed by pharmacists for older adult inpatients with CNCP. Patients and Methods: We evaluated a set of medication review QIs-with previously established face and content validity-for a population of older adult inpatients diagnosed with CNCP. Subjects were in geriatrics wards in a tertiary hospital in Switzerland. Over two phases, pre- and post-QI implementation (Phase 1: July 2023 to April 2024, Phase 2: January to May 2025), pharmacists evaluated QIs for their applicability to the population, potential to improve medication reviews, acceptability by pharmacists, implementation issues and impact. These domains were used to evaluate the measurement properties of QIs in clinical practice, acting as proxies for clinical validity. Evaluations were interpreted using descriptive statistics. Results: We included 89 patients in phase 1 and 48 in phase 2. Of the 38 QIs evaluated, 27 (71%) were applicable to ≥ 5% of patients, 21 (55%) showed the potential to improve medication reviews, 12 (32%) revealed relevant treatment discrepancies that pharmacists accepted, 6 (16%) were rated as problematic to implement, 10 (37%) were impactful according to our predefined criterion and 6 (16%) met all criteria. Conclusion: The clinical evaluation of our set of previously developed QIs could help pharmacists to efficiently detect medication-related problems among vulnerable older adult populations with CNCP. The fact that only a few of the QIs were clinically valid means that future research is required, including the measurement of the influence of these QIs on patient-reported outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.